Extended Data Fig 3. Heat map of off-target activities of lead compounds at potential CNS drug targets.

Radioligand binding assays were carried out by the National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) as described previously^56,57 (on-line protocols available at http://pdsp.med.unc.edu/pdspw/binding.php). Values represent mean binding affinities (pK_i, n=2–4). Affinities lower than a pK_i of 5, or less than 50% inhibition at 10 μM, are shown as a minimum of 5 on the pK_i scale. The hERG inhibition activity was tested in a hERG functional assay as previously published⁵⁹. ND for not determined; BZP for benzodiazepine receptor; DAT for dopamine transporter; NAT for norepinephrine transporter; SERT for serotonin transporter; DOR for delta (δ) opioid receptor; MOR for mu (μ) opioid receptor; KOR for kappa (κ) opioid receptor; PBR for peripheral benzodiazepine binding site; AMPA for aminomethylphosphonic acid receptor; KA for kainate acid receptor; NMDA for N-methyl-D-aspartate receptor; hERG for human Ether-a-go-go-related Gene (potassium channel Kv11.1).